Trials / Completed
CompletedNCT01442948
CD16+ Monocytes in Coronary Heart Disease (CHD)
CD16+ Monocytes in Patients With Coronary Heart Disease
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,000 (actual)
- Sponsor
- Martin-Luther-Universität Halle-Wittenberg · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Monocytes may be separated into phenotypically and functionally distinct cell types by the presence or absence of the lipopolysaccharide receptor CD14 and the Fcγ-receptor CD16. The investigators hypothesize that the total numbers of CD16+ monocytes are significantly related to cardiovascular outcome in patients with angiographically proven coronary heart disease.
Conditions
Timeline
- Start date
- 2007-05-01
- Primary completion
- 2009-08-01
- Completion
- 2010-12-01
- First posted
- 2011-09-29
- Last updated
- 2011-09-29
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01442948. Inclusion in this directory is not an endorsement.